Nature Communications (Aug 2022)
An intranasal ASO therapeutic targeting SARS-CoV-2
- Chi Zhu,
- Justin Y. Lee,
- Jia Z. Woo,
- Lei Xu,
- Xammy Nguyenla,
- Livia H. Yamashiro,
- Fei Ji,
- Scott B. Biering,
- Erik Van Dis,
- Federico Gonzalez,
- Douglas Fox,
- Eddie Wehri,
- Arjun Rustagi,
- Benjamin A. Pinsky,
- Julia Schaletzky,
- Catherine A. Blish,
- Charles Chiu,
- Eva Harris,
- Ruslan I. Sadreyev,
- Sarah Stanley,
- Sakari Kauppinen,
- Silvi Rouskin,
- Anders M. Näär
Affiliations
- Chi Zhu
- Department of Nutritional Sciences & Toxicology, University of California
- Justin Y. Lee
- Department of Nutritional Sciences & Toxicology, University of California
- Jia Z. Woo
- Whitehead Institute for Biomedical Research
- Lei Xu
- Department of Nutritional Sciences & Toxicology, University of California
- Xammy Nguyenla
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley
- Livia H. Yamashiro
- Department of Molecular and Cell Biology, Division of Immunology and Pathogenesis, University of California
- Fei Ji
- Department of Molecular Biology, Massachusetts General Hospital
- Scott B. Biering
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley
- Erik Van Dis
- Department of Molecular and Cell Biology, Division of Immunology and Pathogenesis, University of California
- Federico Gonzalez
- Department of Nutritional Sciences & Toxicology, University of California
- Douglas Fox
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley
- Eddie Wehri
- The Henry Wheeler Center for Emerging and Neglected Diseases, University of California
- Arjun Rustagi
- Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, School of Medicine
- Benjamin A. Pinsky
- Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, School of Medicine
- Julia Schaletzky
- The Henry Wheeler Center for Emerging and Neglected Diseases, University of California
- Catherine A. Blish
- Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, School of Medicine
- Charles Chiu
- Department of Laboratory Medicine, University of California
- Eva Harris
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley
- Ruslan I. Sadreyev
- Department of Molecular Biology, Massachusetts General Hospital
- Sarah Stanley
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley
- Sakari Kauppinen
- Center for RNA Medicine, Aalborg University
- Silvi Rouskin
- Whitehead Institute for Biomedical Research
- Anders M. Näär
- Department of Nutritional Sciences & Toxicology, University of California
- DOI
- https://doi.org/10.1038/s41467-022-32216-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
Despite approved vaccines and anti-virals to prevent and treat SARS-CoV-2 infection, there is a need for further development of efficient antiviral therapeutic strategy. Here, Zhu et al. develop locked nucleic acid antisense oligonucleotides (LNA ASOs) targeting the 5’ leader sequence of SARS-CoV-2 RNA to interfere with replication of wildtype virus and variants of concern. Daily intranasal administration in K18-hACE2 humanized mice suppresses viral infection in lung.
